$BBIO News

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $98

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $110 Price Target

BridgeBio Announces FDA Acceptance Of Its New Drug Application With Priority Review For Oral BBP-418 For The Treatment Of Individuals Living With Limb-Girdle Muscular Dystrophy Type 2I/R9; FDA Sets PDUFA Date Of November 27

Raymond James Downgrades BridgeBio Pharma to Market Perform

Citigroup Initiates Coverage On BridgeBio Pharma with Neutral Rating, Announces Price Target of $82

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow

BridgeBio Submits FDA New Drug Application For Encaleret For Individuals Living With ADH1

BridgeBio Pharma Announces New Data From Its Phase 3 ATTRibute-CM Study At Heart Failure 2026 Meeting, With Data Further Demonstrating Acoramidis's Consistent And Clinically Meaningful Benefit

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

Evercore ISI Group Maintains Outperform on BridgeBio Pharma, Raises Price Target to $130

BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump

BridgeBio Board of Directors Authorized $500M Stock Buyback

BridgeBio Pharma Q1 EPS $(0.84) Misses $(0.67) Estimate, Sales $194.515M Beat $177.937M Estimate

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

BridgeBio Pharma To Present Data From Its Phase 3 ATTRibute-CM Trial In Individuals With Transthyretin Amyloid Cardiomyopathy At Heart Failure 2026

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore

Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $102

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $100 Price Target